High Point Advisor Group LLC Biogen Inc. Transaction History

High Point Advisor Group LLC

$1.7 Billion
Q1 2025

A detailed history of High Point Advisor Group LLC transactions in Biogen Inc. stock. As of the latest transaction made, High Point Advisor Group LLC holds 1,736 shares of BIIB stock, worth $226,304. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,736

Previous 1,934 10.24%

Holding current value

$226,304

Previous $295,000 19.66%

% of portfolio

0.01%

Previous 0.02%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 05, 2025	SELL	$133.43 - $153.27 $26,419 - $30,347	-198 Reduced 10.24%	1,736 $237,000
Q4 2024 Feb 12, 2025	BUY	$146.47 - $191.55 $55,805 - $72,980	381 Added 24.53%	1,934 $295,000
Q3 2024 Nov 04, 2024	SELL	$189.07 - $236.8 $65,418 - $81,932	-346 Reduced 18.22%	1,553 $301,000
Q2 2024 Aug 08, 2024	SELL	$190.52 - $236.72 $1,524 - $1,893	-8 Reduced 0.42%	1,899 $440,000
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $2,120 - $2,677	-10 Reduced 0.52%	1,907 $411,000
Q4 2023 Mar 26, 2024	BUY	$222.59 - $267.94 $426,705 - $513,640	1,917 New	1,917 $496,000
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $230,299 - $273,868	-1,228 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $18,394 - $23,988	65 Added 5.59%	1,228 $348,000
Q2 2021 Jul 29, 2021	BUY	$259.0 - $414.71 $7,252 - $11,611	28 Added 2.47%	1,163 $403,000
Q1 2021 Apr 12, 2021	SELL	$242.95 - $284.63 $2,915 - $3,415	-12 Reduced 1.05%	1,135 $304,000
Q4 2020 Feb 10, 2021	BUY	$236.26 - $355.63 $23,389 - $35,207	99 Added 9.45%	1,147 $309,000
Q3 2020 Nov 06, 2020	BUY	$264.77 - $305.71 $30,183 - $34,850	114 Added 12.21%	1,048 $345,000
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $9,829 - $13,016	38 Added 4.24%	934 $247,000
Q1 2020 May 01, 2020	BUY	$268.85 - $341.04 $169,375 - $214,855	630 Added 236.84%	896 $266,000
Q1 2020 Apr 27, 2020	SELL	$268.85 - $341.04 $162,116 - $205,647	-603 Reduced 69.39%	266 $896,000
Q4 2019 Feb 13, 2020	BUY	$220.06 - $304.07 $12,763 - $17,636	58 Added 7.15%	869 $249,000
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $7,392 - $8,291	-34 Reduced 4.02%	811 $237,000
Q2 2019 Aug 15, 2019	SELL	$219.29 - $241.72 $16,008 - $17,645	-73 Reduced 7.95%	845 $196,000
Q1 2019 May 08, 2019	SELL	$216.71 - $338.96 $480,446 - $751,474	-2,217 Reduced 70.72%	918 $210,000
Q4 2018 Feb 20, 2019	BUY	$278.5 - $352.75 $75,752 - $95,948	272 Added 9.5%	3,135 $1.04 Million
Q3 2018 Oct 24, 2018	BUY	$293.51 - $383.83 $667,735 - $873,213	2,275 Added 386.9%	2,863 $903,000
Q2 2018 Aug 20, 2018	SELL	$257.52 - $306.91 $51,504 - $61,382	-200 Reduced 25.38%	588 $202,000
Q1 2018 Jun 11, 2018	SELL	$260.13 - $367.91 $9,364 - $13,244	-36 Reduced 4.37%	788 $239,000
Q4 2017 Feb 15, 2018	BUY	$307.64 - $344.58 $6,152 - $6,891	20 Added 2.49%	824 $261,000
Q3 2017 Nov 06, 2017	BUY	$281.15 - $329.69 $226,044 - $265,070	804	804 $249,000

Others Institutions Holding BIIB

# of Institutions

1,026

Shares Held

127M

Call Options Held

2.29M

Put Options Held

4.26M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $18.8B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Point Advisor Group LLC with notifications on news.

Account

High Point Advisor Group LLC Biogen Inc. Transaction History